Do you want to read an article? Please log in or register.
Pirfenidone: Molecular Mechanisms and Potential Clinical Applications in Lung Disease
Pulmonary Fibrosis
RECOMMENDED
Related content
RECOMMENDED
Interstitial Lung Disease
Clinical and Functional Characteristics of Patients with Unclassifiable Interstitial Lung Disease (uILD): Long-Term Follow-Up Data from European IPF Registry (eurIPFreg)
★ 2
Recommended by
Dr Martin Frey, Faculty Member
J Clin Med.
Krauss E, El-Guelai M, Pons-Kuehnemann J, Dartsch RC, Tello S, Korfei M, Mahavadi P, Breithecker A, Fink L, Stoehr M, Majeed RW, Seeger W, Crestani B, Guenther A
doi: 10.3390/jcm9082499.
RECOMMENDED
Interstitial Lung Disease
The Spectrum of Interstitial Lung Disease Associated with Autoimmune Diseases: Data of a 3.6-Year Prospective Study from a Referral Center of Interstitial Lung Disease and Lung Transplantation
★ 2
Recommended by
Dr Martin Frey, Faculty Member
J Clin Med.
Atienza-Mateo B, Remuzgo-Martínez S, Mora Cuesta VM, Iturbe-Fernández D, Fernández-Rozas S, Prieto-Peña D, Calderón-Goercke M, Corrales A, Blanco Rodríguez GB, Gómez-Román JJ, González-Gay MÁ, Cifrián JM
doi: 10.3390/jcm9061606.
RECOMMENDED
Interstitial Lung Disease
Computed tomography-based radiomics decodes prognostic and molecular differences in interstitial lung disease related to systemic sclerosis
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Eur Respir J
Schniering J, Maciukiewicz M, Gabrys HS, Brunner M, Blüthgen C, Meier C, Braga-Lagache S, Uldry AC, Heller M, Guckenberger M, Fretheim H, Nakas CT, Hoffmann-Vold AM, Distler O, Frauenfelder T, Tanadini-Lang S, Maurer B
doi: 10.1183/13993003.04503-2020
RECOMMENDED
Interstitial Lung Disease
Closing the Evidence Gap in Interstitial Lung Disease: The Promise of Real World Data
Am J Respir Crit Care Med.
Farrand E, Anstrom KJ, Bernard G, Butte AJ, Iribarren C, Ley B, Martinez F, Collard HR
doi: 10.1164/rccm.
RECOMMENDED
Interstitial Lung Disease
Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet Respir Med.
Maher TM, Corte TJ, Fischer A, Kreuter M, Lederer DJ, Molina-Molina M, Axmann J, Kirchgaessler KU, Samara K, Gilberg F, Cottin V
doi: 10.1016/S2213-2600(19)30341-8.
Interstitial Lung DiseasePulmonary Fibrosis
An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial
J Rheumatol.
Khanna D, Albera C, Fischer A, Khalidi N, Raghu G, Chung L, Chen D, Schiopu E, Tagliaferri M, Seibold JR, Gorina E
doi: 10.3899/jrheum.151322
RECOMMENDED
Interstitial Lung DiseasePulmonary Fibrosis
Pirfenidone for the treatment of interstitial lung disease associated to rheumatoid arthritis: a new scenario is coming?
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
doi: 10.1016/j.rmcr.2020.101051.
RECOMMENDED
EmphysemaInterstitial Lung DiseasePulmonary Fibrosis
Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS® study)
Eur Respir J.
Nasser M, Larrieu S, Si-Mohamed S, Ahmad K, Boussel L, Brevet M, Chalabreysse L, Fabre C, Marque S, Revel D, Thivolet-Bejui F, Traclet J, Zeghmar S, Maucort-Boulch D, Cottin V
doi: 10.1183/13993003.02718-2020.
COMMENTED
Diagnostic Yield of Computed Tomography-Guided Transthoracic Lung Biopsy in Diffuse Lung Diseases
Respiration.
Padrão E, Rodrigues M, Guimarães S, Caetano Mota P, Melo N, Souto Moura C, Morais A, Pereira JM
doi: 10.1159/000489934.